• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Racial disparities persist in the survival of patients with ovarian, colon, and breast cancer

Bioengineer by Bioengineer
December 5, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Three new articles present trends in survival for patients with ovarian, colon, and breast cancer in the United States by race and stage. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings reveal large, consistent, and persistent racial disparities in survival.

For the analyses, a team led by investigators at the Centers for Disease Control and Prevention used information from the second CONCORD study, which reported survival for patients who had cancer diagnosed between 1995 and 2009 in 67 countries and enabled the comparison of survival of patients in the United States with other countries.

In the analysis of ovarian cancer data, researchers found that among the 172,849 ovarian cancers diagnosed from 2001-2009, more than one-half were diagnosed at a distant stage. Five-year net survival was 39.6 percent in 2001-2003 and 41 percent in 2004-2009. Black women had consistently worse survival compared with white women (29.6 percent from 2001-2003 and 31.1 percent from 2004-2009), despite similar stage distributions. Stage-specific survival for all races combined between 2004 and 2009 was 86.4 percent for localized stage, 60.9 percent for regional stage, and 27.4 percent for distant stage.

Concerning colon cancer, the five-year net survival increased 0.9 percent from 63.7 percent during 2001-2003 to 64.6 percent for 2004-2009. Survival improved for both blacks and whites, but the five-year net survival among blacks diagnosed during 2004-2009 had still not reached the level of survival of whites diagnosed during 1990-1994, some 15-20 years earlier. Also, more black than white patients were diagnosed at distant stage in 2001-2003 (21.5 percent versus 17.2 percent, respectively), and in 2004-2009 (23.3 percent versus 18.8 percent).

In the analysis of breast cancer data, five-year net survival was very high (88.2 percent), but survival was more than 10 percentage points lower for black women than for white women–a difference that persisted over time. From 2001-2003, survival was 89.1 percent for white women and 76.9 percent for black women. From 2004-2009, survival was 89.6 percent for white women and 78.4 percent for black women.

###

EMBARGOED until December 5, 2017 at 00:01 AM / 12:01 AM EST by the journal.

Additional Information

Full Citations:

"Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study. Sherri L. Stewart, Rhea Harewood, Melissa Matz, Sun Hee Rim, Susan A. Sabatino, Kevin C. Ward, and Hannah K. Weir. CANCER; Published Online: December 5, 2017 (DOI: 10.1002/cncr.31027).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.31027

"Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study." Arica White, Djenaba Joseph, Sun Hee Rim, Christopher J. Johnson, Michel P. Coleman, and Claudia Allemani. CANCER; Published Online: December 5, 2017 (DOI: 10.1002/cncr.31076).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.31076

"Disparities in breast cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study." Jacqueline W. Miller, Judith Lee Smith, A. Blythe Ryerson, Thomas C. Tucker, and Claudia Allemani. CANCER; Published Online: December 5, 2017 (DOI: 10.1002/cncr.30988).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.30988 Author Contact: CDC News Media Relations Office, at [email protected].

The full supplement issue will be available upon publication at: http://onlinelibrary.wiley.com/doi/10.1002/cncr.v123.S24/issuetoc

About the Journal

CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.

Follow us on Twitter @JournalCancer and Facebook https://www.facebook.com/ACSJournals

About Wiley

Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Media Contact

Dawn Peters
[email protected]

http://newsroom.wiley.com/

http://dx.doi.org/10.1002/cncr.31027

Share12Tweet7Share2ShareShareShare1

Related Posts

Adiposity Changes Impact Hypertension Differently by Life Stage

April 1, 2026
Superagonist µ-Opioid Analgesic Minimizes Side Effects

Superagonist µ-Opioid Analgesic Minimizes Side Effects

April 1, 2026

Inhibiting MD2 May Prevent Bone Metastasis in Prostate Cancer

April 1, 2026

Digital Formulator Powers Fast, Automated Drug Development

April 1, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1006 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Adiposity Changes Impact Hypertension Differently by Life Stage

Superagonist µ-Opioid Analgesic Minimizes Side Effects

Inhibiting MD2 May Prevent Bone Metastasis in Prostate Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.